Chiesi Farmaceutici S.p.a.

This study follows about 100 adults with Fabry disease who are taking or planning to take the drug Elfabrio. Researchers will watch kidney function, heart health, and side effects over time during routine care. The goal is to see how well the drug works and how safe it is in ever…

This study compares a new asthma inhaler that uses a climate-friendly propellant to the current inhaler. About 780 adults with mild to moderate asthma will try both versions to see if they work equally well. The goal is to ensure the greener option is just as effective at control…

This study is testing an experimental drug called PRX-102 in children and teens (ages 2 to under 18) with Fabry disease, a rare genetic disorder. The goal is to see if the drug is safe and helps control the disease by replacing a missing enzyme. About 22 participants will receive…

This study tests a gel called Oleogel-S10 on skin wounds in Japanese children and adults with two types of epidermolysis bullosa (EB), a genetic condition causing fragile skin. The main goal is to see if the gel can close wounds within 45 days and check for any side effects. Part…

This study tests a new enzyme replacement therapy called pegunigalsidase alfa in Japanese patients with Fabry disease, a rare genetic disorder. About 16 people aged 13 to 70 will receive the treatment to see if it is safe and helps control the disease. The goal is to manage sympt…

This study tests an inhaled drug called CHF6333 for safety and tolerability in healthy volunteers and people with bronchiectasis, a lung condition causing chronic cough and infections. The trial starts with single doses in healthy people and patients, then gives repeated doses to…

This early-stage study tests whether a new drug called CHF6467, given as a nasal spray, is safe and tolerable in 68 healthy adults aged 18 to 55. Researchers will also measure how the drug moves in the blood and spinal fluid, and whether the body makes antibodies against it. The …

This study is a worldwide registry that will follow about 10 women with Fabry disease who received the drug pegunigalsidase alfa around the time of pregnancy or while breastfeeding. Researchers will track pregnancy outcomes and infant health for up to one year after birth. The go…